

AMENDMENTS TO THE SPECIFICATION

Please replace the paragraph at page 3, line 27 to page 4, line 4 of the filed specification with the amended paragraphs:

Fig. 1: the result of detecting β -catenin mutation in colon cancer tissue using the inventive β -catenin oligonucleotide microchip; and

Fig. 2: the direct sequencing result of colon cancer tissue which has a β -catenin mutation confirmed by the inventive β -catenin oligonucleotide microchip
[[:]] .

~~Fig. 3: the PCR-SSCP analysis result of colon cancer tissue which has a β -catenin mutation confirmed by the inventive β -catenin oligonucleotide microchip.~~

Please replace the paragraph at page 12, lines 12-23 with the following amended paragraph:

Mutational analysis of the β -catenin gene was performed using the oligonucleotide microarray. As the result of mutational analysis using the inventive β -catenin oligo chip, the 9 β -catenin mutation positive samples in a total of 60 samples were detected. The present inventors compared the 9 β -catenin mutations detected by the β -catenin oligo chip with several techniques, e.g., PCR-SSCP,

DHPLC, direct sequencing, and cloning-sequencing (see Table 2). Automatic direct sequencing, which has been widely used for mutational analysis was not capable of clearly detecting 2 of the 9 β -catenin mutations (see Fig, Fig. 2), and PCR-SSCP also missed one β -catenin mutation (~~see Fig. 3~~). These results might have been caused by excessive wild-type DNA in cancer tissues or by the low sensitivity of these two methods.